Teladoc Health (TDOC) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.6B
Gross Profit
1.8B
70.76%
Operating Income
-208.8M
-8.13%
Net Income
-1.0B
-38.97%
EPS (Diluted)
-$5.87
Balance Sheet Metrics
Total Assets
3.5B
Total Liabilities
2.0B
Shareholders Equity
1.5B
Debt to Equity
1.36
Cash Flow Metrics
Operating Cash Flow
-515.0M
Free Cash Flow
169.6M
Revenue & Profitability Trend
Teladoc Health Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.6B | 2.6B | 2.4B | 2.0B | 1.1B |
| Cost of Goods Sold | 751.3M | 760.0M | 744.0M | 650.3M | 390.8M |
| Gross Profit | 1.8B | 1.8B | 1.7B | 1.4B | 703.1M |
| Operating Expenses | 1.7B | 1.7B | 1.6B | 1.4B | 1.1B |
| Operating Income | -208.8M | -210.5M | -227.4M | -239.0M | -418.2M |
| Pre-tax Income | -993.7M | -219.6M | -13.7B | -384.7M | -576.0M |
| Income Tax | 7.6M | 760.0K | -3.8M | 44.1M | -90.9M |
| Net Income | -1.0B | -220.4M | -13.7B | -428.8M | -485.1M |
| EPS (Diluted) | -$5.87 | -$1.34 | -$84.60 | -$2.73 | -$5.36 |
Income Statement Trend
Teladoc Health Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.7B | 1.5B | 1.3B | 1.2B | 1.1B |
| Non-Current Assets | 1.9B | 2.9B | 3.0B | 16.5B | 16.7B |
| Total Assets | 3.5B | 4.4B | 4.3B | 17.7B | 17.8B |
| Liabilities | |||||
| Current Liabilities | 941.5M | 420.6M | 399.8M | 331.0M | 332.6M |
| Non-Current Liabilities | 1.1B | 1.6B | 1.6B | 1.4B | 1.5B |
| Total Liabilities | 2.0B | 2.1B | 2.0B | 1.7B | 1.9B |
| Equity | |||||
| Total Shareholders Equity | 1.5B | 2.3B | 2.3B | 16.0B | 15.9B |
Balance Sheet Composition
Teladoc Health Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.0B | -220.4M | -13.7B | -428.8M | -485.1M |
| Operating Cash Flow | -515.0M | 304.6M | -13.2B | 166.2M | -110.3M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | 0 | 1.0K | 5.0M | -9.0M | -564.9M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -2.0K | -278.0K | -5.9M | -1.8M | 800.1M |
| Free Cash Flow | 169.6M | 193.7M | 16.5M | 130.1M | -79.6M |
Cash Flow Trend
Teladoc Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.29
Forward P/E
-8.97
Price to Book
0.98
Price to Sales
0.55
PEG Ratio
-8.97
Profitability Ratios
Profit Margin
-39.66%
Operating Margin
-8.73%
Return on Equity
-54.49%
Return on Assets
-3.01%
Financial Health
Current Ratio
1.68
Debt to Equity
111.19
Beta
1.78
Per Share Data
EPS (TTM)
-$5.91
Book Value per Share
$8.14
Revenue per Share
$14.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| tdoc | 1.4B | -1.29 | 0.98 | -54.49% | -39.66% | 111.19 |
| Veeva Systems | 46.0B | 59.92 | 7.39 | 14.06% | 27.34% | 1.24 |
| Ge Healthcare | 32.6B | 14.95 | 3.55 | 26.44% | 11.03% | 97.52 |
| Premier | 1.9B | 21.46 | 1.18 | 6.85% | 4.96% | 19.35 |
| Certara | 1.8B | 104.00 | 1.70 | -0.25% | -0.67% | 28.51 |
| Schrodinger | 1.5B | 44.39 | 4.05 | -43.33% | -83.39% | 31.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.